166 related articles for article (PubMed ID: 25088426)
1. Viral small T oncoproteins transform cells by alleviating hippo-pathway-mediated inhibition of the YAP proto-oncogene.
Nguyen HT; Hong X; Tan S; Chen Q; Chan L; Fivaz M; Cohen SM; Voorhoeve PM
Cell Rep; 2014 Aug; 8(3):707-13. PubMed ID: 25088426
[TBL] [Abstract][Full Text] [Related]
2. β1 integrin-dependent Rac/group I PAK signaling mediates YAP activation of Yes-associated protein 1 (YAP1) via NF2/merlin.
Sabra H; Brunner M; Mandati V; Wehrle-Haller B; Lallemand D; Ribba AS; Chevalier G; Guardiola P; Block MR; Bouvard D
J Biol Chem; 2017 Nov; 292(47):19179-19197. PubMed ID: 28972170
[TBL] [Abstract][Full Text] [Related]
3. Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover.
Hong X; Nguyen HT; Chen Q; Zhang R; Hagman Z; Voorhoeve PM; Cohen SM
EMBO J; 2014 Nov; 33(21):2447-57. PubMed ID: 25180228
[TBL] [Abstract][Full Text] [Related]
4. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
5. The Hippo pathway member Nf2 is required for inner cell mass specification.
Cockburn K; Biechele S; Garner J; Rossant J
Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
[TBL] [Abstract][Full Text] [Related]
6. The polyomavirus middle T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner.
Shanzer M; Ricardo-Lax I; Keshet R; Reuven N; Shaul Y
Oncogene; 2015 Aug; 34(32):4190-8. PubMed ID: 25362852
[TBL] [Abstract][Full Text] [Related]
7. RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway.
Guo PD; Lu XX; Gan WJ; Li XM; He XS; Zhang S; Ji QH; Zhou F; Cao Y; Wang JR; Li JM; Wu H
Cancer Res; 2016 Jul; 76(13):3813-25. PubMed ID: 27325643
[TBL] [Abstract][Full Text] [Related]
8. cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes.
Kim M; Kim M; Lee S; Kuninaka S; Saya H; Lee H; Lee S; Lim DS
EMBO J; 2013 May; 32(11):1543-55. PubMed ID: 23644383
[TBL] [Abstract][Full Text] [Related]
9. The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Shanzer M; Adler J; Ricardo-Lax I; Reuven N; Shaul Y
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1678-1683. PubMed ID: 28154141
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.
Ferraiuolo M; Verduci L; Blandino G; Strano S
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467351
[TBL] [Abstract][Full Text] [Related]
11. A critical role for NF2 and the Hippo pathway in branching morphogenesis.
Reginensi A; Enderle L; Gregorieff A; Johnson RL; Wrana JL; McNeill H
Nat Commun; 2016 Aug; 7():12309. PubMed ID: 27480037
[TBL] [Abstract][Full Text] [Related]
12. Polyomavirus small T antigen interacts with yes-associated protein to regulate cell survival and differentiation.
Hwang JH; Pores Fernando AT; Faure N; Andrabi S; Adelmant G; Hahn WC; Marto JA; Schaffhausen BS; Roberts TM
J Virol; 2014 Oct; 88(20):12055-64. PubMed ID: 25122798
[TBL] [Abstract][Full Text] [Related]
13. LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade.
Tanaka I; Osada H; Fujii M; Fukatsu A; Hida T; Horio Y; Kondo Y; Sato A; Hasegawa Y; Tsujimura T; Sekido Y
Oncogene; 2015 Jan; 34(1):73-83. PubMed ID: 24336325
[TBL] [Abstract][Full Text] [Related]
14. Merlin controls the repair capacity of Schwann cells after injury by regulating Hippo/YAP activity.
Mindos T; Dun XP; North K; Doddrell RD; Schulz A; Edwards P; Russell J; Gray B; Roberts SL; Shivane A; Mortimer G; Pirie M; Zhang N; Pan D; Morrison H; Parkinson DB
J Cell Biol; 2017 Feb; 216(2):495-510. PubMed ID: 28137778
[TBL] [Abstract][Full Text] [Related]
15. Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP.
Rouleau C; Pores Fernando AT; Hwang JH; Faure N; Jiang T; White EA; Roberts TM; Schaffhausen BS
J Virol; 2016 Aug; 90(16):7032-7045. PubMed ID: 27194756
[TBL] [Abstract][Full Text] [Related]
16. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
Li W; Cooper J; Zhou L; Yang C; Erdjument-Bromage H; Zagzag D; Snuderl M; Ladanyi M; Hanemann CO; Zhou P; Karajannis MA; Giancotti FG
Cancer Cell; 2014 Jul; 26(1):48-60. PubMed ID: 25026211
[TBL] [Abstract][Full Text] [Related]
17. Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.
Basu-Roy U; Bayin NS; Rattanakorn K; Han E; Placantonakis DG; Mansukhani A; Basilico C
Nat Commun; 2015 Apr; 6():6411. PubMed ID: 25832504
[TBL] [Abstract][Full Text] [Related]
18. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.
Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X
PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036
[TBL] [Abstract][Full Text] [Related]
19. YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells.
White SM; Avantaggiati ML; Nemazanyy I; Di Poto C; Yang Y; Pende M; Gibney GT; Ressom HW; Field J; Atkins MB; Yi C
Dev Cell; 2019 May; 49(3):425-443.e9. PubMed ID: 31063758
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
